<DOC>
	<DOCNO>NCT02349425</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled , crossover , dose escalation study AF-219 subject Refractory Chronic Cough .</brief_summary>
	<brief_title>A Dose Escalation Study AF-219 Refractory Chronic Cough</brief_title>
	<detailed_description />
	<mesh_term>Cough</mesh_term>
	<criteria>Chest radiograph CT thorax within last 12 month demonstrate abnormality consider significantly contribute chronic cough Refractory chronic cough least one year : cough unresponsive least 8 week target treatment identify underlying trigger include reflux disease , asthma postnasal drip unexplained cough : cough objective evidence underlie trigger determine investigation Score ≥ 40mm Cough Severity VAS Screening Women childbearing potential must use 2 form acceptable birth control method Screening FollowUp Visit . Male subject partner childbearing potential must use 2 method acceptable birth control Screening 3 month last dose study drug . Written informed consent . Willing able comply aspect protocol . Current smoker Individuals give smoking within past 6 month , &gt; 20 packyear smoke history Treatment ACEinhibitor potential cause subject 's cough , require treatment ACEinhibitor study within 4 week prior Baseline Visit ( Day 0 ) FEV1/FVC &lt; 60 % History upper respiratory tract infection recent significant change pulmonary status within 4 week Baseline Visit ( Day 0 ) History opioid use within 1 week Baseline Visit ( Day 0 ) Requiring concomitant therapy prohibit medication Body mass index ( BMI ) &lt; 18 kg/m2 ≥ 37 kg/m2 History concurrent malignancy recurrence malignancy within 2 year prior Screening ( include subject &lt; 3 excise basal cell carcinoma ) History diagnosis drug alcohol dependency abuse within approximately last 3 year Any condition possibly affect drug absorption ( e.g. , gastrectomy , gastroplasty , type bariatric surgery , vagotomy , bowel resection ) Screening systolic blood pressure ( SBP ) &gt; 160 mm Hg diastolic blood pressure ( DBP ) &gt; 90 mm Hg Clinically significant abnormal electrocardiogram ( ECG ) Screening Personal family history congenital long QT syndrome family history sudden death Cardiac pacemaker Significantly abnormal laboratory test Screening Breastfeeding Treatment investigational drug ( except AF219 ) biologic within 60 day precede first dose study medication plan take another investigational drug biologic within 30 day study completion Blood donation within 56 day plasma donation within 7 day prior dose Other severe , acute , chronic medical psychiatric condition laboratory abnormality may increase risk associate trial participation investigational product administration may interfere interpretation trial result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>